EQT reportedly nears €9.6 billion Qiagen acquisition
EQT AB is reportedly nearing a deal to acquire Qiagen N.V., a Netherlands-based molecular-testing company, for approximately €9.6 billion ($10.8 billion), according to people familiar with the matter. No agreement had been announced and a sale was not certain at the time of the report.
Bloomberg reports, citing people familiar with the matter, that EQT AB is nearing a roughly €9.6 billion acquisition of Qiagen N.V. This is new, forward-looking merger information with potentially material implications for Qiagen shareholders, EQT and the competing bidder KKR; it is not merely price commentary. Because the supporting context states that no agreement has been announced and a sale is not certain, the development is described as reported rather than completed or formally announced, with confidence and surprise moderated accordingly. The prior report of EQT’s binding offer above $50 per share is an earlier milestone in the same takeover storyline, so this is not a duplicate and remains linked to existing event 9409. Broader diagnostics competitors and financial advisers are excluded from approved stakeholders because their effects are indirect and speculative.
EQT AB is nearing a deal to acquire Qiagen NV for around €9.6 billion ($10.8 billion) bringing an end to years of takeover speculation involving the European molecular testing company, according to people familiar with the matter.